Related Experiment Videos
Calmodulin-dependent cyclic nucleotide phosphodiesterase in human cerebral cortex and glioblastoma multiforme
S Lal1, R V Raju, R J Macaulay
1Department of Surgery, College of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Canada.
Background:
Calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) has been extensively studied and characterized in normal mammalian tissues; however very little is known about this enzyme in human brain tumors. It has been established that high levels of this enzyme exist in non-central nervous system tumors, PDE inhibitors or cAMP analogues have been used to treat them. This study has examined the levels of CaMPDE in glioblastoma multiforme from six patients and has compared these to the levels of CaMPDE in four patients with normal cerebral tissue. In addition, an enzyme immune assay method (EIA) was developed in this study for the detection of CaMPDE in human cerebral tissue. This method is proposed to be used as an adjunct to the spectrophotometric method presently utilized. This would be beneficial in cases where small tissue samples, for example in stereotactic biopsy, are available.
Methods:
The CaMPDE activity and corresponding levels of expression in cerebral tissue from temporal lobectomies and both surgical extraction or stereotactic biopsy in patients with primary tumors were determined by spectrophotometric and EIA, respectively. The EIA was developed from the production of a polyclonal antibody against bovine brain 60 kDa CaMPDE isozyme. Cross reactivity of the antibody with human was confirmed using transblot and immunohistochemistry.
Results:
Utilising the EIA, there was found to be significant reduction in both catalytic activity (p < 0.001) and in quantitative protein expression (p < 0.001) in glioblastoma multiforme from patients when compared to normal cerebral cortex. Immunoblotting experiments and immunohistochemistry demonstrated that CaMPDE in glioblastoma multiforme failed to react with a polyclonal antibody raised against bovine brain 60 kDa CaMPDE isozyme, whereas the enzyme from normal tissue reacted with antibody.
Conclusions:
Contrary to other studies on non-CNS tumors, the catalytic activity and the protein expression of CaMPDE is reduced in glioblastoma multiforme. The EIA method is a more sensitive in detecting CaMPDE than in the spectrophotometric method, especially when a small amount of tissue is available. Immunohistochemistry and the EIA may be useful in the future to use as markers for other types of brain tumors and not for glioblastoma multiforme as demonstrated.
Insights
Calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) levels are significantly reduced in glioblastoma multiforme compared to normal brain tissue. A newly developed enzyme immune assay (EIA) offers a more sensitive detection method for CaMPDE, especially in small tissue samples.
Area of Science:
- Neuroscience
- Biochemistry
- Oncology
Background:
- Calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) is well-characterized in normal tissues but poorly understood in human brain tumors.
- Elevated CaMPDE levels in non-CNS tumors suggest potential therapeutic strategies using PDE inhibitors.
- This study investigates CaMPDE levels in glioblastoma multiforme (GBM) and normal cerebral tissue.
Purpose of the Study:
- To quantify CaMPDE activity and protein expression in GBM and normal brain tissue.
- To develop and validate an enzyme immune assay (EIA) for CaMPDE detection in human cerebral tissue.
- To compare the sensitivity of EIA with spectrophotometric methods for CaMPDE detection.
Main Methods:
- Spectrophotometry and EIA were used to determine CaMPDE activity and expression in cerebral tissue samples.
- A polyclonal antibody against bovine brain 60 kDa CaMPDE isozyme was generated for EIA development.
- Immunoblotting and immunohistochemistry confirmed antibody cross-reactivity with human CaMPDE.
Main Results:
- Significant reductions in both catalytic activity (p < 0.001) and protein expression (p < 0.001) of CaMPDE were observed in GBM compared to normal cerebral cortex.
- Immunohistochemistry and immunoblotting showed a lack of reaction between GBM CaMPDE and the antibody, unlike normal tissue.
- The developed EIA demonstrated higher sensitivity for CaMPDE detection, particularly with limited tissue samples.
Conclusions:
- Contrary to findings in non-CNS tumors, CaMPDE activity and expression are decreased in glioblastoma multiforme.
- The EIA method provides a more sensitive approach for CaMPDE detection than spectrophotometry, especially for small biopsies.
- Immunohistochemistry and EIA may serve as potential biomarkers for brain tumors, though not specifically for glioblastoma multiforme based on this study.